IMMUNEERING CORPORATION

Immuneering presented at an investor conference Atebimetinib, a third-generation MEK inhibitor, as a new therapeutic approach for first-line treatment of pancreatic cancer. The ongoing phase III MAPKeeper 301 study is active with over 40 centers; top-line results are expected in mid-2028. Earlier phase II data showed a median overall survival of 17.3 months in combination with gemcitabine/nab-paclitaxel, and management emphasized a more favorable tolerability profile and secured financing through the planned readout. » More on de.investing.com

At the Cantor Fitzgerald Global Healthcare Conference, Immuneering reported Phase II results for atebimetinib as first‑line treatment in pancreatic cancer: median overall survival was 17.3 months versus 8.5 months in the historical MPACT benchmark. The company highlights a favorable tolerability profile—84% of evaluable patients maintained or gained weight—and serious events were increased in only a few adverse‑event categories. A global Phase III study with more than 40 active sites is already under way, with top‑line results expected in 2028; atebimetinib is intended to combine tumor control with fewer side effects and could change first‑line treatment if the Phase III data are convincing. » More on de.investing.com

Immuneering reports preclinical results on Atebimetinib in Cancer Research: the dual MEK inhibitor showed antitumor activity in KRAS-, NRAS- and BRAF-mutated models and resists RAF-mediated bypass signaling. In direct comparisons, Atebimetinib inhibited tumor growth more strongly than binimetinib and lowered pERK and pMEK levels, with a short-lived, deep cyclic inhibition mechanism described. In a cachexia model, treated animals’ body weight remained stable for longer. Immuneering is recruiting patients for the phase 3 MAPKeeper 301 study and plans to start a phase 2 study in the second half of the year combining Atebimetinib with Libtayo in RAS-mutant NSCLC. » More on de.investing.com